Nitrofurantoin

Generic Name: Nitrofurantoin

Brand Names: Furadantin, Macrobid, Macrodantin

Drug Type: Small Molecule

Chemical Formula: C_₈H_₆N_₄O_₅

CAS Number: 67-20-9

Unique Ingredient Identifier: 927AH8112L

Background: Nitrofurantoin is a nitrofuran antibiotic used to treat uncomplicated urinary tract infections. Nitrofurantoin is converted by bacterial nitroreductases to electrophilic intermediates which inhibit the citric acid cycle as well as synthesis of DNA, RNA, and protein. This drug is more resistant to the development of bacterial resistance because it acts on many targets at once. Nitrofurantoin is a second line treatment to trimethoprim/sulfamethoxazole.

Nitrofurantoin was granted FDA approval on 6 February 1953.

Indication: Nitrofurantoin is indicated to treat acute uncomplicated urinary tract infections.

Associated Conditions: Acute Cystitis, Urinary Tract Infection

Clinical Trials

Role of Prophylactic Postoperative Antibiotics in HoLEP

Phase 4

Conditions: Urinary Tract Infections
Benign Prostatic Hyperplasia

Interventions: Procedure: Holmium Laser Enucleation of prostate
Drug: Nitrofurantoin
Drug: Cephalexin
Drug: Sulfamethoxazole Trimethoprim Combination
Drug: Ciprofloxacin

First Posted Date: 2022-03-10

Last Posted Date: 2022-03-11

Lead Sponsor: Baylor Research Institute

Target Recruit Count: 100

Registration Number: NCT05274672

Locations: 🇺🇸
Einstein Healthcare network, Philadelphia, Pennsylvania, United States
🇺🇸
Baylor Scott and White, Temple, Texas, United States

EXtended Use of FOsfomycin for the Treatment of CYstitis in Primary Care

Phase 3

Terminated

Conditions: Urinary Tract Infections

Interventions: Drug: Fosfomycin
Drug: Nitrofurantoin

First Posted Date: 2022-02-24

Last Posted Date: 2022-03-15

Lead Sponsor: MJM Bonten

Target Recruit Count: 13

Registration Number: NCT05254808

Locations: 🇳🇱
UMC Utrecht, Utrecht, Netherlands
🇳🇱
Medisch Centrum Heuvelrug, Doorn, Utrecht, Netherlands
🇳🇱
Huisartsenpraktijk Binnenstad, Utrecht, Netherlands

and more 1 locations

Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections

Phase 1

Completed

Conditions: Uncomplicated Urinary Tract Infections
Urinary Tract Infections

Interventions: Drug: GSK3882347
Drug: Nitrofurantoin
Drug: Placebo

First Posted Date: 2021-12-01

Last Posted Date: 2025-01-28

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 140

Registration Number: NCT05138822

Locations: 🇺🇸
GSK Investigational Site, Missouri City, Texas, United States

Effect of Nitrofurantion Used as an Intracanal Medicament

Early Phase 1

Conditions: Intracanal Medication

Interventions: Drug: Nitrofurantoin capsules

First Posted Date: 2021-10-12

Last Posted Date: 2021-10-12

Lead Sponsor: Cairo University

Target Recruit Count: 38

Registration Number: NCT05074628

Clinical Effectiveness and Bacteriological Eradication of 4 Short-course Antibiotics for Uncomplicated UTIs in Women.

Phase 4

Recruiting

Conditions: Urinary Tract Infections

Interventions: Drug: Fosfomycin Trometamol Salt
Drug: Nitrofurantoin
Drug: Pivmecillinam

First Posted Date: 2021-07-13

Last Posted Date: 2023-12-11

Lead Sponsor: Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina

Target Recruit Count: 1000

Registration Number: NCT04959331

Locations: 🇪🇸
Calatayud Center, Calatayud, Aragón, Spain
🇪🇸
Parque Goya Health Center, Zaragoza, Aragón, Spain
🇪🇸
Montblanc Center, Montblanc, Catalonia, Spain

and more 30 locations